GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (XTER:B8FK) » Definitions » Cyclically Adjusted PB Ratio

Biofrontera AG (XTER:B8FK) Cyclically Adjusted PB Ratio : (As of Jun. 03, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Biofrontera AG Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Biofrontera AG Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Biofrontera AG's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG Cyclically Adjusted PB Ratio Chart

Biofrontera AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 13.88 7.13 1.65

Biofrontera AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.22 3.78 2.39 1.65 -

Competitive Comparison of Biofrontera AG's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera AG's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biofrontera AG's Cyclically Adjusted PB Ratio falls into.



Biofrontera AG Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Biofrontera AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Biofrontera AG's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.353/125.0381*125.0381
=5.353

Current CPI (Mar. 2024) = 125.0381.

Biofrontera AG Quarterly Data

Book Value per Share CPI Adj_Book
201406 3.817 99.543 4.795
201409 1.979 99.823 2.479
201412 -0.015 99.543 -0.019
201503 -1.722 99.717 -2.159
201506 -2.958 100.417 -3.683
201509 -4.291 100.417 -5.343
201512 -3.061 99.717 -3.838
201603 -0.463 100.017 -0.579
201606 0.661 100.717 0.821
201609 -1.580 101.017 -1.956
201612 7.825 101.217 9.667
201703 6.133 101.417 7.561
201706 5.039 102.117 6.170
201709 2.350 102.717 2.861
201712 1.640 102.617 1.998
201803 9.616 102.917 11.683
201806 7.608 104.017 9.145
201809 5.689 104.718 6.793
201812 7.167 104.217 8.599
201903 5.908 104.217 7.088
201906 11.010 105.718 13.022
201909 6.214 106.018 7.329
201912 4.341 105.818 5.129
202003 1.859 105.718 2.199
202006 2.066 106.618 2.423
202009 -0.472 105.818 -0.558
202012 3.021 105.518 3.580
202103 9.080 107.518 10.560
202106 7.642 108.486 8.808
202109 5.630 109.435 6.433
202112 20.340 110.384 23.040
202203 10.595 113.968 11.624
202206 7.537 115.760 8.141
202209 5.735 118.818 6.035
202212 6.693 119.345 7.012
202303 5.553 122.402 5.673
202306 5.616 123.140 5.703
202309 4.570 124.195 4.601
202312 6.576 123.773 6.643
202403 5.353 125.038 5.353

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biofrontera AG  (XTER:B8FK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Biofrontera AG Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Biofrontera AG's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofrontera AG (XTER:B8FK) Business Description

Traded in Other Exchanges
Address
Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Biofrontera AG (XTER:B8FK) Headlines

No Headlines